Jeffrey M. Dayno Sells 19,293 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Stock

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) CEO Jeffrey M. Dayno sold 19,293 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $40.13, for a total transaction of $774,228.09. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Harmony Biosciences Stock Performance

Shares of Harmony Biosciences stock traded down $0.65 on Thursday, reaching $38.01. The stock had a trading volume of 961,233 shares, compared to its average volume of 581,495. The business’s 50-day moving average price is $34.66 and its two-hundred day moving average price is $35.05. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.20 and a current ratio of 3.24. Harmony Biosciences Holdings, Inc. has a fifty-two week low of $28.14 and a fifty-two week high of $41.61. The stock has a market cap of $2.17 billion, a P/E ratio of 18.01, a price-to-earnings-growth ratio of 0.53 and a beta of 0.78.

Harmony Biosciences (NASDAQ:HRMY) last released its earnings results on Tuesday, October 29th. The company reported $0.79 EPS for the quarter, beating the consensus estimate of $0.64 by $0.15. The firm had revenue of $186.00 million during the quarter, compared to analysts’ expectations of $184.07 million. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The business’s quarterly revenue was up 16.0% compared to the same quarter last year. During the same period in the prior year, the company earned $0.63 EPS. On average, sell-side analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current year.

Wall Street Analysts Forecast Growth

HRMY has been the topic of several analyst reports. Mizuho lifted their target price on shares of Harmony Biosciences from $42.00 to $52.00 and gave the stock an “outperform” rating in a research report on Thursday, October 10th. HC Wainwright reaffirmed a “buy” rating and set a $75.00 price objective on shares of Harmony Biosciences in a research report on Thursday, January 16th. Oppenheimer reaffirmed an “outperform” rating and set a $59.00 price objective (up from $56.00) on shares of Harmony Biosciences in a research report on Wednesday, October 30th. Needham & Company LLC reaffirmed a “buy” rating and set a $52.00 price objective on shares of Harmony Biosciences in a research report on Monday, January 13th. Finally, Raymond James reaffirmed an “outperform” rating and set a $40.00 price objective on shares of Harmony Biosciences in a research report on Thursday, October 10th. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $55.00.

Institutional Investors Weigh In On Harmony Biosciences

A number of hedge funds have recently added to or reduced their stakes in HRMY. Envestnet Asset Management Inc. grew its holdings in Harmony Biosciences by 19.8% during the 2nd quarter. Envestnet Asset Management Inc. now owns 61,397 shares of the company’s stock worth $1,852,000 after acquiring an additional 10,167 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in Harmony Biosciences by 13.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 956,785 shares of the company’s stock valued at $28,871,000 after purchasing an additional 112,197 shares during the period. Hsbc Holdings PLC lifted its position in Harmony Biosciences by 208.1% during the 2nd quarter. Hsbc Holdings PLC now owns 23,800 shares of the company’s stock valued at $731,000 after purchasing an additional 16,076 shares during the period. Profund Advisors LLC raised its position in shares of Harmony Biosciences by 11.1% in the 2nd quarter. Profund Advisors LLC now owns 7,557 shares of the company’s stock valued at $228,000 after acquiring an additional 758 shares during the period. Finally, Public Sector Pension Investment Board raised its position in shares of Harmony Biosciences by 2.9% in the 2nd quarter. Public Sector Pension Investment Board now owns 70,020 shares of the company’s stock valued at $2,113,000 after acquiring an additional 1,955 shares during the period. Institutional investors own 86.23% of the company’s stock.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.